I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Home > News and Publications > JHM Publications > Promise and Progress > Promise & Progress: Special Issue Bloomberg - Kimmel Institute for Cancer Immunotherapy
Promise and Progress - Margareta Augustine Fellowship Supports Young Investigators
Promise & Progress: Special Issue Bloomberg - Kimmel Institute for Cancer Immunotherapy
Issue No. 2016
Issue No. 2016
Margareta Augustine Fellowship Supports Young Investigators
Date: March 23, 2016
The race to better understand and treat cancer is often hampered by time and funding constraints, and it is even more difficult for our young investigators. A generous $1 million gift from Meg Augustine will ease those constraints for some of our dedicated young scientists.
The Margareta Augustine Fellowship will directly benefit the Kimmel Caner Center’s fellowship training program in breast cancer, blood and bone marrow cancers, and brain cancer. “In my association with Johns Hopkins Medicine over the years, I have been enormously impressed with the dedication of everyone whom I have met. It is my hope that this contribution will help bring about one more step of this lifesaving work,” says Augustine, who has been a member of the Kimmel Cancer Center Advisory Board since 2001.
“The funding is instrumental in helping all of our three fellows complete their research,” says Ben Ho Park, M.D., Ph.D. “Typically there is only a limited amount of funds for each fellow, and any additional research support is the responsibility of the mentor and fellow. The Margareta Augustine Fellowship allows us to increase the research training so that fellows can have the time needed to complete their research, publish and then acquire the best academic position possible.”
One of the inaugural fellows is William “Brian” Dalton, M.D., Ph.D. “Brian is working on a novel gene that is mutated in a number of human cancers. The goal is to recreate lab models of cancers that carry these mutations, develop targeted therapies and companion diagnostics for these mutations, and then eventually move this into clinical trials,” Park says.
Articles in this Issue
- Construction Begins On New Skip Viragh Outpatient Cancer Building
- Sidney Kimmel Helping Others
- Bloomberg ~ Kimmel Institute Cements Progress in Cancer Immunotherapy
- McConkey Named Director of Greenberg Bladder Cancer Institute
- Swim Across America Baltimore Raises Record Funds
- Margareta Augustine Fellowship Supports Young Investigators
- Patients Kept Cozy This Winter